Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study
- PMID: 28919249
- PMCID: PMC6818411
- DOI: 10.1016/j.prro.2017.07.010
Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study
Abstract
Purpose: The purpose of this study is to identify dosimetric variables that best predict for acute esophagitis in patients treated for locally advanced non-small cell lung cancer in a prospectively accrued statewide consortium.
Methods and materials: Patients receiving definitive radiation therapy for stage II-III non-small cell lung cancer within the Michigan Radiation Oncology Quality Consortium were included in the analysis. Dose-volume histogram data were analyzed to determine absolute volumes (cc) receiving doses from 10 to 60 Gy (V10, V20, V30, V40, V50, and V60), as well as maximum dose to 2 cc (D2cc), mean dose (MD), and generalized equivalent uniform dose (gEUD). Logistic regression models were used to characterize the risk of toxicity as a function of dose and other covariates. The ability of each variable to predict esophagitis, individually or in a multivariate model, was quantified by receiver operating characteristic analysis.
Results: There were 533 patients who met study criteria and were included; 437 (81.9%) developed any grade of esophagitis. Significant variables on univariate analysis for grade ≥2 esophagitis were concurrent chemotherapy, V20, V30, V40, V50, V60, MD, D2cc, and gEUD. For grade ≥3 esophagitis, the predictive variables were: V30, V40, V50, V60, MD, D2cc, and gEUD. In multivariable modeling, gEUD was the most significant predictor of both grade ≥2 and grade ≥3 esophagitis. When gEUD was excluded from the model, D2cc was selected as the most predictive variable for grade ≥3 esophagitis. For an estimated risk of grade ≥3 esophagitis of 5%, the threshold values for gEUD and D2cc were 59.3 Gy and 68 Gy, respectively.
Conclusions: In this study, we report the novel finding that gEUD and D2cc, rather than MD, were the most predictive dose metrics for severe esophagitis. To limit the estimated risk of grade ≥3 esophagitis to <5%, thresholds of 59.3 Gy and 68 Gy were identified for gEUD and D2cc, respectively.
Copyright © 2017 Elsevier Inc. All rights reserved.
Figures


Similar articles
-
Factors associated with acute esophagitis during radiation therapy for lung cancer.Radiother Oncol. 2024 Aug;197:110349. doi: 10.1016/j.radonc.2024.110349. Epub 2024 May 28. Radiother Oncol. 2024. PMID: 38815695
-
Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):995-1002. doi: 10.1016/j.ijrobp.2004.12.025. Int J Radiat Oncol Biol Phys. 2005. PMID: 15990000
-
Dosimetric and clinical predictors of acute esophagitis in lung cancer patients in Turkey treated with radiotherapy.Asian Pac J Cancer Prev. 2013;14(7):4223-8. doi: 10.7314/apjcp.2013.14.7.4223. Asian Pac J Cancer Prev. 2013. PMID: 23991980
-
Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy.Radiat Oncol. 2014 Feb 15;9:54. doi: 10.1186/1748-717X-9-54. Radiat Oncol. 2014. PMID: 24528546 Free PMC article.
-
Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. doi: 10.1016/j.ijrobp.2004.12.052. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029785 Review.
Cited by
-
Enhanced prediction of postoperative radiotherapy-induced esophagitis in non-small cell lung cancer: Dosiomic model development in a real-world cohort and validation in the PORT-C randomized controlled trial.Thorac Cancer. 2023 Oct;14(28):2839-2845. doi: 10.1111/1759-7714.15068. Epub 2023 Aug 19. Thorac Cancer. 2023. PMID: 37596813 Free PMC article. Clinical Trial.
-
Radiation-Induced Esophagitis in Non-Small-Cell Lung Cancer Patients: Voxel-Based Analysis and NTCP Modeling.Cancers (Basel). 2022 Apr 5;14(7):1833. doi: 10.3390/cancers14071833. Cancers (Basel). 2022. PMID: 35406605 Free PMC article.
-
Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels.Transl Oncol. 2018 Feb;11(1):102-108. doi: 10.1016/j.tranon.2017.11.005. Epub 2017 Dec 18. Transl Oncol. 2018. PMID: 29220828 Free PMC article.
-
Using inflammatory indexes and clinical parameters to predict radiation esophagitis in patients with small-cell lung cancer undergoing chemoradiotherapy.Front Oncol. 2022 Nov 22;12:898653. doi: 10.3389/fonc.2022.898653. eCollection 2022. Front Oncol. 2022. PMID: 36483030 Free PMC article.
-
Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy.North Clin Istanb. 2023 Mar 28;10(2):172-180. doi: 10.14744/nci.2023.53896. eCollection 2023. North Clin Istanb. 2023. PMID: 37181055 Free PMC article.
References
-
- Bradley JD. Paulus R, Komaki, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carbo-platin plus paclitaxcl with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–199. - PMC - PubMed
-
- Palma DA, Senan S, Oberjie C, et al. Predicting esophagitis after chcmoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;87: 690–696. - PubMed
-
- Moran JM, Feng M, Benedetti L, et al. Development of a model web-based system to support a statewide quality consortium in radiation oncology. Pract Radiat Oncol. 2017;7:e205–e213. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous